International Clinical Trial: A Phase 3 Trial to Evaluate the Safety and Immunogenicity of VLA1553 in Healthy Children Aged 1 to 11 Years

Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07133178) titled 'A Phase 3 Trial to Evaluate the Safety and Immunogenicity of VLA1553 in Healthy Children Aged 1 to 11 Years' on Aug. 13.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).

Primary Sponsor: Valneva Austria GmbH

Condition: Chikungunya Virus Infection

Intervention: Biological: VLA1553

Recruitment Status: Not recruiting

Phase: Phase 3

Date of First Enrollment: February 6, 2026

Target Sample Size: 3000

To know more, visit https://clinicaltrials...